FDA Approval: Adagrasib for KRAS G12C NSCLC
Podcast | English | 30 Min
Image For Activity Cover
Credit
No Credit Offered
This week, the FDA granted accelerated approval to Adagrasib to treat advanced NSCLC with a KRAS G12C mutation after at least one prior line of systemic therapy. In this episode of Lung Cancer Considered, host Dr. Stephen Liu and two guests discuss the approval and what impact it will have on patients and clinicians. Joining the podcast are Dr. Joshua Sabari (@JSabari), assistant professor of Medicine and Thoracic Oncologist at NYU Perlmutter Cancer Center in New York City, and Dr. Sheena Bhalla (@SheenaBhallaMD), assistant professor of Medicine and Thoracic Oncologist at UT Southwestern Medical Center in Dallas.

Podcast Hosts:

  • Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA 

Podcast Guests: 

  • Sheena Bhalla, MD, Assistant Professor in the Department of Internal Medicine, UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, Dallas, TX
  • Joshua Sabari, MD, Director Inpatient Medical Oncology, NYU Langone Health, New York, NY, USA
Powered By